单剂量巴比可以预防脑疟疾的
N J White1, S Looareesuwan, R E Phillips
1Bangkok Hospital for Tropical Diseases, Faculty of Tropical Medicine, Mahidol University, Thailand.
Lancet (London, England)
|July 9, 1988
概括
单次注射法诺巴比能有效地预防脑性疟疾儿童的. 这种简单,具有成本效益的治疗方法在临床试验中显著降低了发作发生率,没有副作用.
科学领域:
- 儿科神经学 儿科神经学
- 传染性疾病 传染性疾病
- 临床药理学 临床药理学
背景情况:
- 大脑疟疾是疟疾的严重并发症,特别是在儿童中.
- 是大脑疟疾的常见和危险的神经表现.
研究的目的:
- 评估单次肌内注射法诺巴比在预防脑疟疾儿科患者随后的疗效.
主要方法:
- 这是一项双盲,安慰剂控制的研究,涉及48名患有严格定义的大脑疟疾的儿科患者 (年龄大于6岁).
- 患者接受了单次肌内注射费诺巴比 (3.5 mg/kg) 或安慰剂.
主要成果:
- 费诺巴比显著降低了随后的发生率,从安慰剂组的54%降至费诺巴比组的12.5%.
- 单次肌肉内注射phenobarbitone没有报告任何不良反应.
结论:
- 单次肌肉内注射法诺巴比是一种安全,有效和简单的方法,可以预防脑疟疾的.
- 这种干预提供了一种低成本的策略,以缓解儿科疟疾严重的神经复杂症.
相关概念视频
Sedatives and Hypnotics Drugs: Barbiturates
Sedatives and hypnotics encompass a drug class that acts on the central nervous system (CNS) to alleviate anxiety, promote relaxation and induce sleep.These drugs function by amplifying the actions of the neurotransmitter γ-aminobutyric acid (GABA), resulting in reduced neuronal activity. Barbiturates, a subset of sedatives and hypnotics first synthesized in the late 1800s, are categorized into ultra-short, short, intermediate, and long-acting groups based on their duration of effect. A key...
Antiepileptic Drugs: GABAergic Pathway Potentiators
γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for their...
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for their...
Antiepileptic Drugs: Potassium Channel Activators
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Ezogabine has gained approval as an adjunctive treatment...
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption
Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
Malaria
Malaria pathogenesis in humans reflects a delicate interplay between parasite biology and host response. Clinical illness reflects a host’s immune response to the parasite’s asexual replication cycle, which is often asymptomatic in individuals with partial immunity. From the parasite's perspective, transmission between mosquito and human with minimal host pathology is evolutionarily advantageous. Among the six Plasmodium species infecting humans, P. falciparum and P. vivax dominate in global...
Antiprotozoal Agents
Leishmaniasis is a widespread parasitic disease caused by several Leishmania species. It affects millions of people each year and remains a major public health problem in endemic regions. First-line treatment relies on pentavalent antimonials, including meglumine antimoniate and sodium stibogluconate. Even so, how these drugs work has not been fully clear, especially their interaction with parasite-specific biochemical pathways. One key target is trypanothione reductase (TR), an enzyme that...


